Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 11, 2010, Pages 1709-1718

  Witzel, Isabell D ^a   Milde Langosch, Karin ^a   Wirtz, Ralph M ^b   Roth, Claudia ^b   Ihnen, Maike ^a   Mahner, Sven ^a   Zu Eulenburg, Christine ^a   Jänicke, Fritz ^a   Müller, Volkmar ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b SIEMENS AG   (Germany)

Author keywords

Breast cancer; HER2; mRNA; PAI 1; uPA

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; DNA PROBE; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PRIMER DNA; PROGESTERONE RECEPTOR; RNA;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER SURVIVOR; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TISSUE SECTION; BREAST NEOPLASMS; DNA MICROARRAY; DNA PROBE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DNA PRIMERS; DNA PROBES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE; TREATMENT OUTCOME; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77957594028     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0829-4     Document Type: Article

References (30)

1. K Annecke M Schmitt U Euler M Zerm D Paepke S Paepke G von Minckwitz C Thomssen N Harbeck 2008 uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial Adv Clin Chem 45 31 45 1:CAS:528:DC%2BD1cXmtF2isrY%3D 10.1016/S0065-2423(07)00002-9 18429492
2. J Bergqvist JF Ohd J Smeds S Klaar J Isola H Nordgren GP Elmberger H Hellborg J Bjohle AL Borg L Skoog J Bergh 2007 Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome Ann Oncol 18 845 850 1:STN:280:DC%2BD2s3ns1yhug%3D%3D 10.1093/annonc/mdm059 17351254 (Pubitemid 47054080)
3. JC Biermann L Holzscheiter M Kotzsch T Luther M Kiechle-Bahat FC Sweep PN Span M Schmitt V Magdolen 2008 Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA Int J Mol Med 21 251 259 1:CAS:528: DC%2BD1cXitF2ltLs%3D 18204793
4. P Birner G Oberhuber J Stani C Reithofer H Samonigg H Hausmaninger E Kubista W Kwasny D Kandioler-Eckersberger M Gnant R Jakesz 2001 Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer Clin Cancer Res 7 1669 1675 1:STN:280:DC%2BD3MzkslagtA%3D%3D 11410505
5. J Bogaerts F Cardoso M Buyse S Braga S Loi JA Harrison J Bines S Mook N Decker P Ravdin P Therasse E Rutgers LJ van't Veer M Piccart 2006 Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial Nat Clin Pract Oncol 3 540 551 1:CAS:528:DC%2BD28XhtFKqtbzE 10.1038/ncponc0591 17019432 (Pubitemid 44781724)
6. WP Carney R Neumann A Lipton K Leitzel S Ali CP Price 2003 Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer Clin Chem 49 1579 1598 1:CAS:528:DC%2BD3sXnvVyhtrc%3D 10.1373/49.10.1579 14500583 (Pubitemid 37194212)
7. R Castello A Estelles C Vazquez C Falco F Espana SM Almenar C Fuster J Aznar 2002 Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer Clin Chem 48 1288 1295 1:CAS:528:DC%2BD38XlslKktrs%3D 12142386
8. R Castello F Espana C Vazquez C Fuster SM Almenar J Aznar A Estelles 2006 Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity Thromb Res 117 487 492 1:CAS:528:DC%2BD28XitValtb4%3D 10.1016/j.thromres.2005.03.025 15907980 (Pubitemid 43326132)
9. R Castello JM Landete F Espana C Vazquez C Fuster SM Almenar LA Ramon KP Radtke A Estelles 2007 Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer Thromb Res 120 753 762 1:CAS:528:DC%2BD2sXpsFKrt7o%3D 10.1016/j.thromres.2006. 12.016 17258797 (Pubitemid 47268042)
10. S Di Cosimo J Baselga 2008 Targeted therapies in breast cancer: where are we now? Eur J Cancer 44 2781 2790 10.1016/j.ejca.2008.09.026 19013786
11. M Dowsett AK Dunbier 2008 Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer Clin Cancer Res 14 8019 8026 1:CAS:528:DC%2BD1cXhsV2it7rM 10.1158/1078-0432.CCR-08-0974 19088018
12. FJ Esteva AA Sahin M Cristofanilli K Coombes SJ Lee J Baker M Cronin M Walker D Watson S Shak GN Hortobagyi 2005 Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy Clin Cancer Res 11 3315 3319 1:CAS:528:DC%2BD2MXjslOqtro%3D 10.1158/1078-0432.CCR-04-1707 15867229 (Pubitemid 40627881)
13. LM Gjerdrum BS Sorensen E Kjeldsen FB Sorensen E Nexo S Hamilton-Dutoit 2004 Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis J Mol Diagn 6 42 51 1:CAS:528:DC%2BD2cXhslGnu7w%3D 14736826
14. N Harbeck C Thomssen U Berger K Ulm RE Kates H Hofler F Jaenicke H Graeff M Schmitt 1999 Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse Breast Cancer Res Treat 54 147 157 1:STN:280:DyaK1MzltFKqsw%3D%3D 10.1023/A:1006118828278 10424405 (Pubitemid 29295317)
15. N Harbeck RE Kates MP Look ME Meijer-Van Gelder JG Klijn A Kruger M Kiechle F Jaenicke M Schmitt JA Foekens 2002 Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424) Cancer Res 62 4617 4622 1:CAS:528:DC%2BD38XmsVShs7k%3D 12183417
16. F Jaenicke M Schmitt L Pache K Ulm N Harbeck H Hofler H Graeff 1993 Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer Breast Cancer Res Treat 24 195 208 10.1007/BF01833260
17. G Konecny M Untch J Arboleda C Wilson S Kahlert B Boettcher M Felber M Beryt S Lude H Hepp D Slamon M Pegram 2001 Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer Clin Cancer Res 7 2448 2457 1:CAS:528:DC%2BD3MXmsVOmtLk%3D 11489825
18. P Leissner T Verjat T Bachelot M Paye A Krause A Puisieux B Mougin 2006 Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer BMC Cancer 6 216 10.1186/1471-2407-6-216 16945123 (Pubitemid 44420306)
19. V Mueller C Thomssen C Karakas I Eustermann J Ramirez Porras C Coith J Berger T Loning F Jaenicke K Pantel 2003 Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay Int J Biol Markers 18 13 20 1:CAS:528:DC%2BD3sXlvVSrsbg%3D
20. V Mueller I Witzel H Lück G Köhler G vMinckwitz V Möbus D Sattler T Löning W Wilczak F Jaenicke K Pantel C Thomssen 2004 Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer Breast Cancer Res Treat 86 9 18 1:CAS:528:DC%2BD2cXltFWmsrc%3D 10.1023/B:BREA.0000032919. 83803.48 (Pubitemid 38918894)
21. Y Nagamine RL Medcalf P Munoz-Canoves 2005 Transcriptional and posttranscriptional regulation of the plasminogen activator system Thromb Haemost 93 661 675 1:CAS:528:DC%2BD2MXjs1ersbs%3D 15841310
22. S Paik S Shak G Tang C Kim J Baker M Cronin FL Baehner MG Walker D Watson T Park W Hiller ER Fisher DL Wickerham J Bryant N Wolmark 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817 2826 1:CAS:528:DC%2BD2MXhslymsw%3D%3D 10.1056/NEJMoa041588 15591335 (Pubitemid 40051905)
23. EA Perez VJ Suman NE Davidson S Martino PA Kaufman WL Lingle PJ Flynn JN Ingle D Visscher RB Jenkins 2006 HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial J Clin Oncol 24 3032 3038 10.1200/JCO.2005.03.4744 16809727 (Pubitemid 46638937)
24. JS Ross C Hatzis WF Symmans L Pusztai GN Hortobagyi 2008 Commercialized multigene predictors of clinical outcome for breast cancer Oncologist 13 477 493 10.1634/theoncologist.2007-0248 18515733 (Pubitemid 351872866)
25. BO Schlemmer BS Sorensen J Overgaard KE Olsen LM Gjerdrum E Nexo 2004 Quantitative PCR-new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization Scand J Clin Lab Invest 64 511 522 1:CAS:528:DC%2BD2cXlvVKltrg%3D 10.1080/00365510410002922 15276916 (Pubitemid 39070629)
26. F Spyratos C Bouchet S Tozlu M Labroquere S Vignaud V Becette R Lidereau I Bieche 2002 Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer Anticancer Res 22 2997 3003 1:CAS:528: DC%2BD3sXosl2gsQ%3D%3D 12530032
27. MD Sternlicht AM Dunning DH Moore PD Pharoah DG Ginzinger K Chin JW Gray FM Waldman BA Ponder Z Werb 2006 Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression Cancer Epidemiol Biomarkers Prev 15 2107 2114 1:CAS:528:DC%2BD28Xht1aisrbN 10.1158/1055-9965.EPI-06-0351 17119035 (Pubitemid 44877033)
28. LJ van't Veer S Paik DF Hayes 2005 Gene expression profiling of breast cancer: a new tumor marker J Clin Oncol 23 1631 1635 10.1200/JCO.2005.12.005 15755970 (Pubitemid 46211417)
29. U Vinatzer B Dampier B Streubel M Pacher MJ Seewald C Stratowa K Kaserer M Schreiber 2005 Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization Clin Cancer Res 11 8348 8357 1:CAS:528:DC%2BD2MXht1KjsrnP 10.1158/1078-0432.CCR-05-0841 16322295 (Pubitemid 41746947)
30. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik MD Pegram EA Perez MF Press A Rhodes C Sturgeon SE Taube R Tubbs GH Vance M van de Vijver TM Wheeler DF Hayes 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 1:CAS:528:DC%2BD2sXht1ejs7Y%3D 10.1200/JCO.2006.09.2775 17159189 (Pubitemid 350003059)